Somavert
Payments companies reported to CMS as associated with Somavert. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Somavert, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Somavert
These are the largest totals companies reported as associated with Somavert. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Aristides Maniatis | Centennial, CO | Pediatric Endocrinology | $7,744.26 |
| Vivien Bonert | Los Angeles, CA | Endocrinology, Diabetes & Metabolism | $3,791.95 |
| Beverly Biller | Boston, MA | Endocrinology, Diabetes & Metabolism | $3,000.00 |
| Elena Christofides | Columbus, OH | Endocrinology, Diabetes & Metabolism | $2,317.29 |
| Rebekah Dailidonis | Orlando, FL | Pediatrics (Nurse Practitioner) | $1,260.00 |
| Yun Feng | New York, NY | Endocrinology, Diabetes & Metabolism | $588.06 |
| Philip Rabito | New York, NY | $525.78 | |
| Stuart Weiss | New York, NY | Endocrinology, Diabetes & Metabolism | $507.44 |
| Andrew Martorella | New York, NY | Endocrinology, Diabetes & Metabolism | $455.47 |
| Minisha Sood | New York, NY | Endocrinology, Diabetes & Metabolism | $454.07 |
Prescribed Somavert?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.